Immunotherapy for Gastric Cancer: 26 Real Stories

26 stories match gastric cancer and immunotherapy. 23 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Gastric cancer treatment during hemodialysis after liver recurrence

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: HER2-negative

Metastatic Site: liver|peritoneum

The cancer progressed in the peritoneum despite treatment, and systemic therapy was stopped in August 2024 before transfer to hospice in October 2024.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Gastric CancerGastric Cancer

Stage IV AFP-producing gastric cancer responds to chemotherapy and immunotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: HER2-negative; pMMR; elevated AFP

Metastatic Site: liver|peritoneum

Imaging showed a sustained partial response, his AFP level returned to normal, and he continued maintenance serplulimab at the latest follow-up.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Severe skin reaction after immunotherapy for metastatic gastric cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: pMMR; PD-L1 CPS ~10; HER2 1+

Metastatic Site: liver

He recovered from the severe treatment-related skin reaction and was discharged after 32 days, with sintilimab permanently discontinued.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Stage IV gastric cancer with benign breast hemangioma during ramucirumab therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Gastric cancer: HER2 negative, PD-L1 TPS >=5%

Metastatic Site: peritoneum; preaortic lymph nodes; omentum

After initial response to FOLFOX/nivolumab and temporary benefit from paclitaxel/ramucirumab and FOLFIRI, the gastric cancer progressed to massive ascites. Trifluridine/tipiracil was attempted, but she died from rapid disease progression.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Gastric CancerGastric Cancer

ALK-Fusion Gastric Cancer Responds to Alectinib Before Progression

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: DCTN1–ALK fusion; ATM p.E1724*; CDK6 amplification; HER2 negative; mismatch-repair proteins intact; later KRAS amplification

Metastatic Site: bone

Alectinib produced a partial response for about 11.5 months, but the cancer later progressed systemically and she died from uncontrollable gastrointestinal bleeding.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Stage IV Gastric Cancer Responds to Nivolumab Before Severe Immune Hepatitis

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: HER2 1+; PD-L1 tumor-cell score 5%; mismatch-repair proteins intact; p53 mutated

Metastatic Site: liver

After an initial reduction in the gastric tumor and liver metastases, nivolumab was stopped for severe hepatitis and later disease progression with multi-organ failure was documented.

PubMed Central
OutcomeSetback / Progression
Mark, who was diagnosed with Stage IV Gastric CancerGastric Cancer

Stage IV Gastric Cancer: Mark's Patient Story

Patient Info: Mark Scragg, male, Under 40 | Stage IV

Biomarkers: Lynch syndrome

After 3 months of chemotherapy and immunotherapy, scans showed no sign of the stomach tumor. By the 2025 article, Mark had finished active treatment, felt well, and his cancer was described as remaining largely in remission.

Dana-Farber
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Metastatic gastric cancer with an ATM mutation responding to olaparib

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: Pathogenic germline ATM mutation, HER2-negative, PD-L1 15%

Metastatic Site: peritoneum

He had a deep response lasting about 18 months, but imaging in December 2023 again showed peritoneal carcinomatosis.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Metastatic hepatoid gastric adenocarcinoma achieving complete remission with sintilimab

Patient Info: Anonymized, male | Stage IV

Biomarkers: AFP markedly elevated

Metastatic Site: liver

By the fifth sintilimab cycle, gastroscopy showed no gastric tumor, CT showed no liver metastases and AFP had normalized; complete remission was confirmed and remained stable during subsequent treatment.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

HER2-positive metastatic gastric cancer responding to trastuzumab deruxtecan rechallenge

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver

After trastuzumab deruxtecan was restarted, his symptoms improved after the first cycle and imaging showed tumor shrinkage after 3 cycles. He was still receiving treatment without progression at the latest follow-up.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Long-term complete response to nivolumab after recurrent Stage IV gastric cancer

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: HER2-negative, PD-L1 CPS ≤1

Metastatic Site: peritoneum, distant lymph nodes

About 7 years after surgery and roughly 3 years after starting nivolumab, CT showed no recurrent nodules or enlarged lymph nodes. She remained on nivolumab with a complete clinical response, had regained weight and returned to work.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Gastric CancerGastric Cancer

Kidney Injury During Nivolumab Treatment for Stage IV Gastric Cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Kidney function and proteinuria improved after nivolumab was stopped, but the gastric cancer progressed. Restarted nivolumab was ineffective, and treatment was changed to irinotecan.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Sjögren syndrome during nivolumab treatment for HER2-positive metastatic gastric cancer

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, lungs, adrenal gland

One year after nivolumab was stopped, the shrinkage of lung metastases was maintained and the adrenal metastasis remained unchanged, although severe dry-mouth symptoms from treatment-related Sjögren syndrome persisted.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Gastric AdenocarcinomaGastric Cancer

MSI-High Gastric Cancer With a Complete Response to Preoperative Nivolumab

Patient Info: Anonymized, Female, 60s

Biomarkers: MSI-high; PD-L1 expression in more than 1% of tumor cells; HER2 negative

Surgery found a complete pathologic response with no residual tumor cells and no cancer in 12 lymph nodes. At the time of reporting, she had no complaints and had returned to normal activities.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Gastric CancerGastric Cancer

Graves disease during nivolumab treatment for HER2-positive metastatic gastric cancer

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, brain

After progression through several treatment lines and development of brain metastasis, he died 4 months after evaluation for nivolumab-associated Graves disease, more than 1.5 years after his Stage IV gastric-cancer diagnosis.

PubMed Central
OutcomeIn Memory